Aura has received IND clearance from the U.S. FDA for its lead program, light-activated AU-011 in ocular melanoma (OM). This active IND enables Aura to begin initial clinical testing of AU-011, a unique targeted therapy that could transform the primary treatment of patients with OM.
Aura secured an additional $8 million round of funding to advance AU-011 to the clinic. The company also announced the addition of Henri Termeer, former CEO of Genzyme and major Aura investor, to its Board of Directors, and welcomed key new Clinical Advisory Board (CAB) members, all distinguished ocular oncologists.
We are Developing a New Class of Therapies to Target and Destroy Cancer Cells Selectively
Current treatments for cancers like ocular melanoma are highly invasive and often imprecise and toxic. We are creating a new class of therapies that can pinpoint solid tumors and metastases without harming surrounding tissue, enabling targeted treatment across a wide range of cancers.
Dr. Jay Duker has been a practicing ophthalmologist for more than 30 years and is also a professor as well as head of a prominent center of care in the Boston area, the New England Eye Center. In this Q&A, Dr. Duker shares his thoughts on how ocular melanoma (OM) treatment has evolved over the years and what advances are on the horizon.
The first time I heard the words, “ocular melanoma” was at The University of Colorado Cancer Center in Denver.
My healthy husband, Gregg, who, at the age of 34, had never had an eye exam in his life, had just been diagnosed with OM.